Skip to main content
LENZ logo

LENZ Therapeutics, Inc.

LENZNASDAQHealthcareBiotechnology

$3.15Today:- (-)1Y −89.64%

As of Oct 26, 2026 close

Market cap
$98.67M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$3.12$36.43
Volume (live)
-
Avg. volume (3M)
758.40K

LENZ Therapeutics (LENZ) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), LENZ Therapeutics used $69.17M of cash in operating activities and spent $827.00K on capital expenditures. That left free cash flow of −$70.00M.

LENZ Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for LENZ Therapeutics, Inc. (LENZ) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-82.13-49.77-69.97-101.05-70.76-68.37-0.11
Depreciation & Amortization0.290.060.022.350.730.120.00
Stock Based Compensation12.556.371.340.720.200.000.00
Change in Working Capital3.25-13.099.416.011.151.710.01
Change in Accounts Receivable-0.330.000.000.000.000.000.00
Change in Inventory-4.280.000.000.000.000.000.00
Change in Accounts Payable-0.09-4.280.860.191.830.59-0.01
Change in Other Working Capital-3.03-8.818.55-8.69-5.671.120.02
Other Operating Activities-3.13-2.95-1.184.3911.8057.820.08
Net Cash from Operating Activities-69.17-59.39-60.38-4.09-5.39-8.72-0.02
Investing Activities
Capital Expenditures-0.83-0.47-0.03-0.04-0.01-1.550.00
Purchases of Investments-280.80-241.91-52.09-405.520.000.000.00
Sales/Maturities of Investments205.9687.9022.50170.250.000.000.00
Net Cash from Investing Activities-75.67-154.48-29.62-0.04-0.01-1.550.00
Financing Activities
Common Stock Issued149.7579.510.000.68251.9530.080.00
Common Stock Repurchased0.000.000.00-0.080.000.000.00
Other Financing Activities0.00119.4980.700.000.310.000.00
Net Cash from Financing Activities149.75199.0080.7030.2622.7730.080.00
Summary
Effect of Forex Changes on Cash0.000.000.000.00-1.720.000.03
Net Change in Cash4.91-14.87-9.3026.1317.3619.810.01
Cash at Beginning of Period20.2735.1444.44376.980.950.010.00
Cash at End of Period25.1820.2735.1447.7318.3119.820.01
Free Cash Flow-70.00-59.86-60.41-4.13-5.40-10.27-0.02

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About LENZ Therapeutics Cash Flow

What is LENZ Therapeutics's free cash flow?

LENZ Therapeutics had negative free cash flow of $70.00M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$69.17M minus $827.00K of capital expenditures.

How much does LENZ Therapeutics spend on capital expenditures?

LENZ Therapeutics spent $827.00K on capital expenditures in fiscal 2025, compared with $468.00K a year earlier.

Does LENZ Therapeutics pay dividends or buy back shares?

LENZ Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition